Stocks Health care TRAW
NASDAQ · Health careTraws Pharma, Inc. (TRAW)
It posted a net loss of $21.6M. In fiscal 2024 capital spending exceeded operating cash flow by $20.8M. At June 30, 2026 it held $5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Traws Pharma, Inc.
- Net worth
- Traws Pharma, Inc. has a market value (market cap) of $3.8M at the latest share price, and shareholders' equity of $1.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2024 operations used $18.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Traws Pharma, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Traws Pharma, Inc. does
Traws Pharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TRAW.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2024 | $2.8M | $9.2M | $0.82 | -$20.8M |
| 2024 | $226K | -$166.5M | -$35.21 | -$33.4M |
| 2023 | $226K | -$18.9M | -$22.57 | -$17.9M |
| 2022 | $226K | -$19M | -$22.82 | n/a |
| 2021 | $226K | -$16.2M | -$24.07 | n/a |
| 2020 | $231K | -$25.2M | -$54.42 | -$23.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where TRAW ranks in Health care
Latest SEC filings
What Traws Pharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026
- August 14, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 12, 2026Passive stake changed SCHEDULE 13G/A
- July 31, 2026
- July 10, 2026Other event 8-K
- July 9, 2026
- July 1, 2026
Insider trades
What the people running Traws Pharma, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| April 16, 2026 | Orbimed Advisors LLC10% owner | Boughtindirect | 597,729 | $998.2K |
| December 12, 2025 | Parker Charles NolanChief Financial Officer | Received as pay | 15,393 | - |
| December 12, 2025 | Stover Jack EDirector | Received as pay | 6,157 | - |
| December 12, 2025 | Cautreels WernerDirector | Received as pay | 4,874 | - |
| December 12, 2025 | Leaman John HaroldDirector | Received as pay | 4,058 | - |
| December 12, 2025 | Dukes Iain D.Chief Executive Officer, Director | Received as pay | 36,943 | - |
| December 12, 2025 | Shoemaker Mary TeresaDirector | Received as pay | 6,157 | - |
| December 12, 2025 | Clarke TraffordDirector | Received as pay | 6,157 | - |
Who owns TRAW
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Orbimed Advisors LLC13D, may seek influence with 1 related filers | 11.9% | May 5, 2026 |
| Alyeska Investment Group, L.P.13G, passive with 2 related filers | 9.9% | February 14, 2025 |
| Sirenia Capital Management LP13G, passive with 1 related filers | 9.9% | August 14, 2026 |
| Ikarian Capital, LLC13G, passive with 1 related filers | 9.5% | August 14, 2026 |
| Chernett Jorey13G, passive | 6.8% | January 16, 2026 |
| Perceptive Advisors LLC13G, passive with 2 related filers | 6.1% | May 15, 2026 |
Largest institutional holders
Insiders
11 insiders reported holding 1,902,163 shares in total, about $475.5K at the last price.
| Holder | Shares |
|---|---|
| Orbimed Advisors LLC10% owner | 1,203,2501,203,250 held indirectly |
| Dukes Iain D.Chief Executive Officer, Director | 171,130 |
| Savchuk NikolayChief Operating Officer, Director | 150,606 |
| Pauza Charles DavidChief Science Officer Virology | 115,971 |
| Redfield RobertChief Medical Officer | 113,919 |
| Cautreels WernerDirector | 109,222 |
| Parker Charles NolanChief Financial Officer | 15,393 |
| Shoemaker Mary TeresaDirector | 6,292 |
| Stover Jack EDirector | 6,165 |
| Clarke TraffordDirector | 6,157 |
Questions about TRAW
What does Traws Pharma, Inc. do?
Traws Pharma, Inc. is a company in the Health care sector, listed on NASDAQ as TRAW. Its shares trade on NASDAQ under the ticker TRAW.
What is Traws Pharma, Inc.'s net worth?
Traws Pharma, Inc. has a market value (market cap) of $3.8M at the latest share price, and shareholders' equity of $1.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Traws Pharma, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $21.6M.
When did Traws Pharma, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026.
When is Traws Pharma, Inc.'s next earnings report?
Traws Pharma, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare TRAW with
Follow TRAW
Get an email when Traws Pharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Traws Pharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.